Ikarian Capital, LLC Mirati Therapeutics, Inc. Put Options Transaction History

Ikarian Capital, LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $98,565 - $196,261	-1,300 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $171,769 - $230,684	1,300 New	1,300 $231,000
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $23.3 Million - $29.1 Million	-162,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $61.5 Million - $85.8 Million	-387,000 Reduced 70.49%	162,000 $27.8 Million
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $45.2 Million - $66.7 Million	399,000 Added 266.0%	549,000 $91.2 Million
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $79,211 - $132,429	1,100 Added 0.74%	150,000 $17.1 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $6.98 Million - $11.6 Million	100,000 Added 204.5%	148,900 $11.4 Million
Q4 2019 Jan 31, 2020	BUY	$70.76 - $128.86 $3.46 Million - $6.3 Million	48,900 New	48,900 $6.3 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.